Enterprise capital deal volumes within the European life sciences sector reached a record-breaking stage in 2021. Nonetheless, financing volumes decreased considerably by 29% within the first 4 months of 2022 in comparison with 2021.
Â
Our deal knowledge and sentiment calculations recommend that the cooldown of the life sciences capital markets has now reached European enterprise markets. Primarily based on these observations, we count on tougher fundraising campaigns for European healthcare firms over the subsequent couple of months.